

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 August 2023 (03.08.2023)



(10) International Publication Number
WO 2023/144559 A1

(51) International Patent Classification:

C07D 417/14 (2006.01) A61K 31/427 (2006.01)
C07D 471/04 (2006.01) A61K 31/4192 (2006.01)
C07D 487/04 (2006.01) A61K 31/517 (2006.01)
C07D 491/10 (2006.01) A61K 31/537 (2006.01)
C07D 498/10 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/GB2023/050195

(22) International Filing Date:

27 January 2023 (27.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2201151.4 28 January 2022 (28.01.2022) GB

(71) Applicant: **ADORX THERAPEUTICS LIMITED**
[GB/GB]; 137a George Street, Edinburgh, Lothian EH2
4JY (GB).

(72) Inventors: **MCCARTHY, Clive**; c/o AdoRx Therapeutics
Limited, 137a George Street, Edinburgh, Lothian EH2 4JY
(GB). **MOULTON, Ben**; c/o Apex Molecular Ltd, The Bio-
hub at Alderley Park, Alderley Edge, Mereside, Cheshire
SK10 4TG (GB).

(74) Agent: **HGF LIMITED**; 1 City Walk, Leeds, West York-
shire LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: ANTAGONIST OF ADENOSINE RECEPTORS



I

(57) Abstract: The present invention relates to compounds of formula I shown below: wherein R₁, R₄, R₅ and R₆ are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a and/or A2b receptor activity is implicated, such as, for example, cancer.

WO 2023/144559 A1